ObjectiveTo determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trialMethodsA multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored.Results52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three meal-related symptoms was 15.3% among patients receiving acotiamide compared with 9.0% in the placebo group (p=0.004). The significant benefit of acotiamide over placebo in OTE and elimination rate was maintained during the 4 week post-treatment follow-up. All other secondary efficacy end points, including quality of life, were significantly improved with 100 mg of acotiamide as compared with placebo. The number needed to treat was 6 for OTE and 16 for symptom elimination rate. The incidence of adverse events was similar between the acotiamide group and placebo group and no significant cardiovascular effects due to treatment were seen.ConclusionsOver 4 weeks, acotiamide significantly improved symptom severity and eliminated meal-related symptoms in patients with FD.Trial registration numberhttp://ClinicalTrials.gov number, NCT00761358.

No abstract

A van der Waals (vdW) heterostructure composed of multivalley systems can show excitonic optical responses from interlayer excitons that originate from several valleys in the electronic structure. In this work, we studied photoluminescence (PL) from a vdW heterostructure, WS/MoS, deposited on hexagonal boron nitride (hBN) flakes. PL spectra from the fabricated heterostructures observed at room temperature show PL peaks at 1.3-1.7 eV, which are absent in the PL spectra of WS or MoS monolayers alone. The low-energy PL peaks we observed can be decomposed into three distinct peaks. Through detailed PL measurements and theoretical analysis, including PL imaging, time-resolved PL measurements, and calculation of dielectric function ε(ω) by solving the Bethe-Salpeter equation with G W, we concluded that the three PL peaks originate from direct K-K interlayer excitons, indirect Q-Γ interlayer excitons, and indirect K-Γ interlayer excitons.

Acotiamide significantly enhances GAR and GER in FD patients. Acotiamide may have therapeutic potential for FD patients.

We characterized the longitudinal field formed at a tightly focused spot by a high numerical aperture objective lens using a tip-enhanced near-field microscope. The longitudinal field efficiently excites the localized surface plasmon polaritons at the metallic tip apex resulting in an electric field enhancement. Radially polarized light generated by a combination of four half-waveplates successfully increases the longitudinal field resulting in higher sensitivity for tip-enhanced Raman spectroscopy of adenine nanocrystals.

The relatively well-known mirror reaction method of forming silver films has been used to produce substrates for surface enhanced Raman scattering (SERS). The simple and convenient method produces a thin metal film on silicon that shows an order of magnitude superior surface enhancement properties when compared to a conventional SERS substrate made by vacuum evaporation. Of particular interest is that the method is ideal for coating atomic force microscope probes for apertureless scanning near-field spectroscopy which is usually made difficult by the damage caused by evaporative coating and annealing.

These results suggest that acotiamide possesses efficacy on FD and more specifically its meal-related symptoms of FD.

Localized surface plasmon resonances were controlled at deep-ultraviolet (DUV) wavelengths by fabricating aluminum (Al) nanostructures in a size-controllable manner. Plasmon resonances were obtained at wavelengths from near-UV down to 270 nm (4.6 eV) depending on the fabricated structure size. Such precise size control was realized by the nanosphere lithography technique combined with additional microwave heating to shrink the spaces in a close-packed monolayer of colloidal nanosphere masks. By adjusting the microwave heating time, the sizes of the Al nanostructures could be controlled from 80 nm to 50 nm without the need to use nanosphere beads of different sizes. With the outstanding controllability and versatility of the presented fabrication technique, the fabricated Al nanostructure is promising for use as a DUV plasmonic substrate, a light-harvesting platform for mediating strong light-matter interactions between UV photons and molecules placed near the metal nanostructure. V